SGLT‐2 inhibitors and GLP‐1 receptor agonists for Type 2 diabetes

Academic Emergency MedicineEarly View THE BRASS TACKS: CONCISE REVIEWS OF PUBLISHED EVIDENCE SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes Esteban Davila MD, Corresponding Author Esteban Davila MD [email protected] orcid.org/0009-0007-8558-0209 Department of Emergency Medicine, New York City Health + Hospitals/Kings County, Brooklyn, New York, USA Correspondence Esteban Davila, Department of Emergency Medicine, New York City Health + Hospitals/Kings County, 451 Clarkson Ave, Brooklyn, NY 11203, USA. Email: [email protected]Search for more papers by this authorJames McCormack BSc (Pharm), PharmD, James McCormack BSc (Pharm), PharmD Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, CanadaSearch for more papers by this author Esteban Davila MD, Corresponding Author Esteban Davila MD [email protected] orcid.org/0009-0007-8558-0209 Department of Emergency Medicine, New York City Health + Hospitals/Kings County, Brooklyn, New York, USA Correspondence Esteban Davila, Department of Emergency Medicine, New York City Health + Hospitals/Kings County, 451 Clarkson Ave, Brooklyn, NY 11203, USA. Email: [email protected]Search for more papers by this authorJames McCormack BSc (Pharm), PharmD, James McCormack BSc (Pharm), PharmD Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, CanadaSearch for more papers by this author First published: 17 March 2024 https://doi.org/10.1111/acem.14895 Editor's Note: Brass Tacks are concise reviews of published evidence. This series is a result of collaboration between Academic Emergency Medicine and the evidence-based medicine website "www.TheNNT.com." For inquiries please contact the section editor, Shahriar Zehtabchi, MD (email: [email protected]). Supervising Editor: Shahriar Zehtabchi Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. REFERENCES 1 American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021; 44(Suppl 1): S111-S124. doi:10.2337/dc21-S009 10.2337/dc21-S009 PubMedWeb of Science®Google Scholar 2Das S, Everett B, Birtcher K, et al. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes. J Am Coll Cardiol. 2020; 76(9): 1117-1145. doi:10.1016/j.jacc.2020.05.037 10.1016/j.jacc.2020.05.037 CASPubMedWeb of Science®Google Scholar 3Li S, Vandvik PO, Lytvyn L, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ. 2021; 373:n1091. doi:10.1136/bmj.n1091 10.1136/bmj.n1091 PubMedGoogle Scholar 4Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials [published correction appears in BMJ. 2022 Jan 18;376:o109]. BMJ. 2021; 372:m4573. doi:10.1136/bmj.m4573 10.1136/bmj.m4573 PubMedGoogle Scholar 5Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023; 381:e074068. doi:10.1136/bmj-2022-074068 10.1136/bmj-2022-074068 PubMedGoogle Scholar 6Shi Q. Anticipated absolute effects for patients with type 2 diabetes. West China Hospital of Sichuan Hospital. Accessed October 6, 2023. https://qingys.shinyapps.io/data_visualization/ Google Scholar 7Shin H, Schneeweiss S, Glynn RJ, Patorno E. Cardiovascular outcomes in patients initiating first-line treatment of type 2 diabetes with sodium-glucose cotransporter-2 inhibitors versus metformin: a cohort study. Ann Intern Med. 2022; 175(7): 927-937. 10.7326/M21-4012 PubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation